{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:36:30Z","timestamp":1793097390915,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007588","name":"Washington State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100385","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:33:04Z","timestamp":1786059184000},"page":"100385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic characterization of human kinases across tissue types: Implications for kinase-activated drugs"],"prefix":"10.1016","volume":"54","author":[{"given":"Griffin D.","family":"Shaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Subash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-0912","authenticated-orcid":false,"given":"Bhagwat","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2010.02.001","article-title":"Human and viral nucleoside\/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties","volume":"86","author":"Deville-Bonne","year":"2010","journal-title":"Antiviral Res"},{"issue":"7","key":"10.1016\/j.dmd.2026.100385_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","article-title":"Nucleoside analogues and nucleobases in cancer treatment","volume":"3","author":"Galmarini","year":"2002","journal-title":"Lancet Oncol"},{"issue":"5600","key":"10.1016\/j.dmd.2026.100385_bib3","first-page":"1912","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.bi.57.070188.002025","article-title":"Interactions between deoxyribonucleotide and DNA synthesis","volume":"57","author":"Reichard","year":"1988","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100385_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195764","article-title":"Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067","volume":"13","author":"Figueroa","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.dmd.2026.100385_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ebiom.2015.07.008","article-title":"Discovery of genetic variants of the kinases that activate tenofovir in a compartment-specific manner","volume":"2","author":"Lade","year":"2015","journal-title":"EBioMedicine"},{"issue":"suppl 5","key":"10.1016\/j.dmd.2026.100385_bib7","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100385_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","article-title":"In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia","volume":"117","author":"Galmarini","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib9","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/AAC.41.5.1099","article-title":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89","volume":"41","author":"Faletto","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.dmd.2026.100385_bib10","first-page":"3561","article-title":"Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells","volume":"37","author":"Chou","year":"1977","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2026.100385_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejps.2012.11.007","article-title":"Selectivity of kinases on the activation of tenofovir, an anti-HIV agent","volume":"48","author":"Varga","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1080\/15257770903155899","article-title":"Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives","volume":"28","author":"Koch","year":"2009","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00001813-199204000-00012","article-title":"Activity of 2\u2032,2\u2032-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units","volume":"3","author":"Hanauske","year":"1992","journal-title":"Anticancer Drugs"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/0006-2952(94)90207-0","article-title":"Molecular effects of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) on DNA replication in intact HL-60 cells","volume":"48","author":"Ross","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","article-title":"Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes","volume":"75","author":"Seto","year":"1985","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib16","first-page":"42","article-title":"Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5\u2032-triphosphate and response to therapy","volume":"39","author":"Rustum","year":"1979","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood.V64.1.54.54","article-title":"Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells","volume":"64","author":"Kufe","year":"1984","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.dmd.2026.100385_bib18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.107.128595","article-title":"Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants","volume":"323","author":"Lamba","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100385_bib19","first-page":"1165","article-title":"Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells","volume":"34","author":"Song","year":"2009","journal-title":"Int J Oncol"},{"issue":"609","key":"10.1016\/j.dmd.2026.100385_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz0274","article-title":"The human secretome","volume":"12","author":"Uhl\u00e9n","year":"2019","journal-title":"Sci Signal"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib22","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1021\/acs.jproteome.7b00025","article-title":"Quantitative analysis of human red blood cell proteome","volume":"16","author":"Bryk","year":"2017","journal-title":"J Proteome Res"},{"issue":"13","key":"10.1016\/j.dmd.2026.100385_bib23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.dmd.2026.100385_bib24","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1021\/acs.jproteome.5c00455","article-title":"Protein abundance of clinically relevant drug-metabolizing hydrolases in human liver and intestine by targeted versus global proteomics approaches: a comparative study","volume":"24","author":"Singh","year":"2025","journal-title":"J Proteome Res"},{"issue":"6","key":"10.1016\/j.dmd.2026.100385_bib25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cpt.3409","article-title":"Developmental expression of drug transporters and conjugating enzymes involved in enterohepatic recycling: implication for pediatric drug dosing","volume":"116","author":"Thakur","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100385_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.dib.2014.08.004","article-title":"Quantitative analysis of the Escherichia coli proteome","volume":"1","author":"Wi\u015bniewski","year":"2014","journal-title":"Data Brief"},{"issue":"20","key":"10.1016\/j.dmd.2026.100385_bib27","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1007\/s00216-018-1127-2","article-title":"Proteins and antibodies in serum, plasma, and whole blood\u2014size characterization using asymmetrical flow field-flow fractionation (AF4)","volume":"410","author":"Leeman","year":"2018","journal-title":"Anal Bioanal Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-1119(97)00099-1","article-title":"Human type II arginase: sequence analysis and tissue-specific expression","volume":"193","author":"Morris","year":"1997","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/PAS.0b013e3181e5dffa","article-title":"Arginase-1 a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms","volume":"34","author":"Yan","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib30","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.124.001271","article-title":"Biochemistry, pharmacology, and in vivo function of arginases","volume":"77","author":"Heuser","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-065X.2009.00789.x","article-title":"Mannose-binding lectin and innate immunity","volume":"230","author":"Eddie Ip","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.dmd.2026.100385_bib32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/mi.2015.100","article-title":"Role of mannose-binding lectin in intestinal homeostasis and fungal elimination","volume":"9","author":"Choteau","year":"2016","journal-title":"Mucosal Immunol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100385_bib33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1084\/jem.167.3.1034","article-title":"A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins","volume":"167","author":"Ezekowitz","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.dmd.2026.100385_bib79","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1002\/imt2.177","article-title":"ggVennDiagram: intuitive Venn diagram software extended","volume":"3","author":"Gao","year":"2024","journal-title":"iMeta"},{"key":"10.1016\/j.dmd.2026.100385_bib34","unstructured":"Thomson RJ, Moshirfar M, Ronquillo Y. Tyrosine kinase inhibitors. In: StatPearls [Internet]. StatPearls Publishing; 2026. Updated July 18, 2023. Accessed July 7, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563322\/"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FPC.0000000000000040","article-title":"PharmGKB summary abacavir pathway","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmd.2026.100385_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830990","article-title":"Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics","volume":"13","author":"Chatterjee","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100385_bib37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1124\/mol.56.3.562","article-title":"Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme","volume":"56","author":"Van Rompay","year":"1999","journal-title":"Mol Pharmacol"},{"issue":"45","key":"10.1016\/j.dmd.2026.100385_bib38","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib39","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1046\/j.1432-1033.2003.03537.x","article-title":"Reaction of human UMP-CMP kinase with natural and analog substrates","volume":"270","author":"Pasti","year":"2003","journal-title":"Eur J Biochem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1172\/JCI111741","article-title":"Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma","volume":"75","author":"Wiley","year":"1985","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib41","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/1535-7163.MCT-05-0121","article-title":"Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells","volume":"4","author":"Jordheim","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"29","key":"10.1016\/j.dmd.2026.100385_bib42","doi-asserted-by":"crossref","first-page":"21220","DOI":"10.1016\/S0021-9258(19)36820-6","article-title":"Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity","volume":"267","author":"Miller","year":"1992","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(01)00139-5","article-title":"NDP kinase reactivity towards 3TC nucleotides","volume":"50","author":"Kreimeyer","year":"2001","journal-title":"Antiviral Res"},{"issue":"14","key":"10.1016\/j.dmd.2026.100385_bib44","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1074\/jbc.271.14.7887","article-title":"Cellular phosphorylation of anti-HIV nucleosides","volume":"271","author":"Bourdais","year":"1996","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100385_bib45","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"Magee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/acsptsci.3c00250","article-title":"Tenofovir activation is diminished in the brain and liver of creatine kinase brain-type knockout mice","volume":"7","author":"Eberhard","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"10","key":"10.1016\/j.dmd.2026.100385_bib47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1593\/neo.10458","article-title":"Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy","volume":"12","author":"Fujita","year":"2010","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.dmd.2026.100385_bib48","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1021\/acs.molpharmaceut.5b00282","article-title":"Quantitative targeted proteomics of pancreatic cancer: deoxycytidine kinase protein level correlates to progression-free survival of patients receiving gemcitabine treatment","volume":"12","author":"Ohmine","year":"2015","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1476-4598-13-159","article-title":"Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents","volume":"13","author":"Klanova","year":"2014","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.dmd.2026.100385_bib50","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1134\/S0026893321040105","article-title":"Antiviral and antimicrobial nucleoside derivatives: structural features and mechanisms of action","volume":"55","author":"Zenchenko","year":"2021","journal-title":"Mol Biol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00296260","article-title":"Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside","volume":"19","author":"Preisler","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"10.1016\/j.dmd.2026.100385_bib52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2217\/pgs-2018-0086","article-title":"Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients","volume":"19","author":"Elsayed","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dmd.2026.100385_bib53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.21.01422","article-title":"Polygenic Ara-C response score identifies pediatric patients with acute myeloid leukemia in need of chemotherapy augmentation","volume":"40","author":"Elsayed","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100385_bib54","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/bloodadvances.2022009088","article-title":"SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia","volume":"7","author":"Marrero","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.dmd.2026.100385_bib55","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-24-0863","article-title":"Pharmacogenomic score effectively personalizes treatment of acute myeloid leukemia","volume":"30","author":"Marrero","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.11726","article-title":"Pharmacogenomics, race, and treatment outcome in pediatric acute myeloid leukemia","volume":"7","author":"Lamba","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib57","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3109\/10428194.2011.635862","article-title":"The T_T genotype within the NME1 promoter single nucleotide polymorphism \u2013835 C\/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia","volume":"53","author":"Braunagel","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.dmd.2026.100385_bib58","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/cancers15123145","article-title":"Role of intracellular drug disposition in the response of acute myeloid leukemia to cytarabine and idarubicin induction chemotherapy","volume":"15","author":"Rodr\u00edguez-Mac\u00edas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000513696","article-title":"Deoxycytidine kinase (DCK) mutations in human acute myeloid leukemia resistant to cytarabine","volume":"144","author":"Wu","year":"2021","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100385_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104012","article-title":"Comprehensive proteomic profiling of plasma and serum phosphatidylserine-positive extracellular vesicles reveals tissue-specific proteins","volume":"25","author":"Muraoka","year":"2022","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ymthe.2021.07.015","article-title":"Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis","volume":"30","author":"Liu","year":"2022","journal-title":"Mol Ther"},{"issue":"16","key":"10.1016\/j.dmd.2026.100385_bib62","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.7150\/thno.77256","article-title":"Extracellular vesicles: catching the light of intercellular communication in fibrotic liver diseases","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"issue":"16","key":"10.1016\/j.dmd.2026.100385_bib63","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.3390\/cancers14163913","article-title":"Extracellular vesicle-mediated metastasis suppressors NME1 and NME2 modify lipid metabolism in fibroblasts","volume":"14","author":"M\u00e1ty\u00e1si","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.dmd.2026.100385_bib64","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s11064-020-03019-w","article-title":"Extracellular vesicles isolated from human induced pluripotent stem cell-derived neurons contain a transcriptional network","volume":"45","author":"Hicks","year":"2020","journal-title":"Neurochem Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100385_bib65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tibs.2012.11.008","article-title":"Secreted protein kinases","volume":"38","author":"Tagliabracci","year":"2013","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib66","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2014.06.048","article-title":"A secreted tyrosine kinase acts in the extracellular environment","volume":"158","author":"Bordoli","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood.2020010342","article-title":"The secreted tyrosine kinase VLK is essential for normal platelet activation and thrombus formation","volume":"139","author":"Revollo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.dmd.2026.100385_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114270","article-title":"Pharmacological inhibition of MEK1\/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expression","volume":"159","author":"Verzijl","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.dmd.2026.100385_bib69","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12885-015-1754-3","article-title":"Relapsing pneumonitis due to two distinct inhibitors of the MAPK\/ERK pathway: report of a case","volume":"15","author":"Giraud","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.dmd.2026.100385_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dmd.2026.100385_bib71","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.dmd.2026.100385_bib72","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.dmd.2026.100385_bib73","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03445","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.dmd.2026.100385_bib74","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","article-title":"Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors","volume":"101","author":"Kumar","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dmd.2026.100385_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241278039","article-title":"Management and mechanisms of diarrhea induced by tyrosine kinase inhibitors in human epidermal growth factor receptor-2-positive breast cancer","volume":"31","author":"Sun","year":"2024","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.dmd.2026.100385_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.877","article-title":"Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer","volume":"18","author":"Hirsh","year":"2011","journal-title":"Curr Oncol"},{"issue":"19","key":"10.1016\/j.dmd.2026.100385_bib77","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.3390\/ijms21197009","article-title":"Syk inhibitors: new computational insights into their intraerythrocytic action in Plasmodium falciparum malaria","volume":"21","author":"Marchetti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2026.100385_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1652750","article-title":"Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study","volume":"16","author":"Miao","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:20:49Z","timestamp":1793096449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":78,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006549"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100385","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic characterization of human kinases across tissue types: Implications for kinase-activated drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100385"}}